At the time of writing, Syros Pharmaceuticals Inc [SYRS] stock is trading at $0.25, up 19.71%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SYRS shares have gain 25.10% over the last week, with a monthly amount drifted -6.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syros Pharmaceuticals Inc [NASDAQ: SYRS] stock has seen the most recent analyst activity on November 04, 2020, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $15 from $11. Previously, Alliance Global Partners started tracking the stock with Buy rating on September 22, 2020, and set its price target to $18. On January 17, 2020, downgrade downgraded it’s rating to Neutral. ROTH Capital upgraded its rating to Buy for this stock on November 05, 2018. In a note dated March 13, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $11 to $13.
For the past year, the stock price of Syros Pharmaceuticals Inc fluctuated between $0.18 and $8.17. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Syros Pharmaceuticals Inc [NASDAQ: SYRS] shares were valued at $0.25 at the most recent close of the market. An investor can expect a potential return of 1900.0% based on the average SYRS price forecast.
Analyzing the SYRS fundamentals
According to Syros Pharmaceuticals Inc [NASDAQ:SYRS], the company’s sales were 0.39M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at -2.29% with Operating Profit Margin at -288.92%, Pretax Profit Margin comes in at -253.41%, and Net Profit Margin reading is -253.41%. To continue investigating profitability, this company’s Return on Assets is posted at -1.15, Equity is -27.47 and Total Capital is -1.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -3.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1977 points at the first support level, and at 0.1451 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3064, and for the 2nd resistance point, it is at 0.3625.
Ratios To Look Out For
It is important to note that Syros Pharmaceuticals Inc [NASDAQ:SYRS] has a current ratio of 2.25. Further, the Quick Ratio stands at 2.25, while the Cash Ratio is 2.05. Considering the valuation of this stock, the price to sales ratio is 16.67.
Transactions by insiders
Recent insider trading involved AKKARAJU SRINIVAS, Director, that happened on Dec 30 ’24 when 9333.0 shares were purchased. Affiliate, Flagship Pioneering Fund VII, completed a deal on Dec 27 ’24 to buy 1.33 million shares. Meanwhile, Affiliate Flagship VentureLabs IV LLC bought 21333.0 shares on Dec 13 ’24.
